SM
RPRX

Sabby Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Sabby Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,793
Closed -$2.08M – 432
2015
Q3 		$2.08M Buy
2,793
+84
+3% +$642 0.09% 150
2015
Q2 		$1.94M Buy
2,709
+768
+40% +$5.98K 0.07% 165
2015
Q1 		$1.67M Sell
1,941
-1,220
-39% -$10.9K 0.07% 160
2014
Q4 		$3.15K Sell
3,161
-299
-9% -$2.55K 0.1% 93
2014
Q3 		$3.42K Buy
3,460
+10
+0.3% +$148 0.13% 74
2014
Q2 		$5.97M Buy
3,450
+79
+2% +$1.29K 0.26% 54
2014
Q1 		$5.98M Buy
3,371
+436
+15% +$8.44K 0.34% 56
2013
Q4 		$5.37M Sell
2,935
-2,797
-49% -$52.8K 0.34% 47
2013
Q3 		$15.4M Buy
5,732
+3,388
+145% +$72.6K 1% 28
2013
Q2 		$4.33M Buy
+2,344
New +$41.4K 0.29% 68

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sabby Management's RPRX Position: Q3 2015 in Review

Sabby Management sold out of Repros Therapeutics Inc. (RPRX) in Q3 2015, closing a stake of 41,643 shares — an estimated $318K sold.

Sabby Management first reported a position in RPRX in Q2 2013 and held it in 6 quarters. The position peaked at $3.96M in Q3 2013. 58 funds tracked by Wall St. Rank hold RPRX as of Q3 2015.

  • Sabby Management reported no remaining Repros Therapeutics Inc. position as of Q3 2015 after selling out during the quarter.
  • Sabby Management sold 41,643 Repros Therapeutics Inc. shares in Q3 2015, an estimated $318K.
  • Sabby Management first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 6 quarters.
  • Sabby Management's Repros Therapeutics Inc. position peaked at $3.96M in Q3 2013.
  • 58 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2015.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.